Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The increase in glucagon-like peptide-1 (GLP-1) activity has emerged as a useful therapeutic tool for the treatment of type 2 diabetes mellitus. The actions of GLP-1 on β-cells and the nervous and digestive systems are well known. The action of this peptide in adipose tissue (AT), however, is still poorly defined. Furthermore, no relationship has been established between GLP-1 receptor (GLP-1R) in AT and obesity and insulin resistance (IR). We provide evidence for the presence of this receptor in AT and show that its mRNA and protein expressions are increased in visceral adipose depots from morbidly obese patients with a high degree of IR. Experiments with the 3T3-L1 cell line showed the lipolytic and lipogenic dose-dependent effect of GLP-1. Moreover, GLP-1 stimulated lipolysis in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signaling. Our data also demonstrate that the expression of the GLP-1R in AT correlated positively with the homeostasis model assessment index in obese IR subjects. Furthermore, prospective studies carried out with patients that underwent biliopancreatic diversion surgery showed that subjects with high levels of GLP-1R expression in AT, which indicates a deficit of GLP-1 in this tissue, were those whose insulin sensitivity improved after surgery, suggesting the potential relationship between AT GLP-1R and insulin sensitivity amelioration in obese subjects. Altogether these results indicate that the GLP-1/GLP-1R system in AT represents another potential candidate for improving insulin sensitivity in obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, numerous studies have shown that following glucose overload, IR and diabetes clearly exhibit a decrease in circulating GLP-1 [58,67].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, the functional classification of OB individuals based on the degree of IR revealed that, in the context of a very high degree of IR, GLP-1R in VAT depots was significantly up-regulated.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“It is interesting that these authors showed that mature adipocytes and stromal vascular fraction (SVF), which include mesenchymal stem cells (MSCs), preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells like AT macrophages, expressed GLP-1R at both the mRNA and protein levels.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Since the 1990s, reports have indicated that isolated mouse and human adipocytes contain GLP1-R ([58], and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
In the citing paper
“Vendrell et al. [58] firstly reported that GLP-1R in human AT is likely correlated with the degree of IR and that there is a definite up-regulation of GLP-1R at the gene and protein levels in the visceral fat depot in individuals with morbid obesity (OB) and a high degree of IR.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Weyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A., & Pratley, R. E. (2000) · Diabetologia · doi:10.1007/s001250051560 · Cited by 799
Weight Change and Diabetes Incidence: Findings from a National Cohort of US Adults
Ford, E. S., Williamson, D. F., & Liu, S. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009256 · Cited by 624
Gutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457
Cited by
Items 101–173 of 173
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
“…that white adipocytes express GLP-1R at just over 10% of the level found in tissues that are highly responsive to GLP-1, such as the stomach [43 ], other research found little to no GLP-1R expression in adipocytes and substantial expression only in non-adipocyte cells within the tissue,…”
Tavares, G., Silva, D., Simões, F., Eickhoff, H., Marques, D., Sacramento, J. F., Capucho, A. M., Seiça, R. M. F., Conde, S. V., & Matafome, P. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032464 · Cited by 16
“Conversely, GLP1R gene expression and protein levels were described to be increased in the visceral adipose depot in obese patients with a high degree of insulin resistance [22].”
BackgroundIzaguirre, M., Gómez‐Ambrosi, J., Rodríguez, A., Ramírez, B., Becerril, S., Valentí, V., Moncada, R., Unamuno, X., Silva, C., de la Higuera, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040479 · Cited by 14
“the expression of GLP1R in AT and its association with the degree of insulin resistance [38].”
BackgroundPicoli, C. C., Tsibulnikov, S., Ho, M., DeMambro, V., Feng, T., Eltahir, M., Le, P. T., Chlebek, C., Rosen, C. J., Ryzhov, S. V., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00521.2024 · Cited by 13
“GLP-1 receptors are widely expressed in tissues, such as the pancreas (51–53), gastrointestinal tract (54, 55), kidney (16, 56), brain (57, 58), and adipose tissue (59), supporting the diverse physiological benefits of semaglutide (17).”
Craig, S. L., Gault, V. A., Flatt, P. R., & Irwin, N. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114355 · Cited by 14
Masashi, I. I. D. A., & Asano, A. (2024) · Journal of Veterinary Medical Science · doi:10.1292/jvms.24-0042 · Cited by 12
“In adipose tissue, GLP-1 receptor stimulation has been reported to induce lipolysis and brown remodeling [35, 37, 39 ].”
BackgroundAa, B., Serova, M., Chashkina, M. I., Kosharnaia, R. S., Salpagarova, Z. K., Andreev, D. A., & Giverts, I. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.06 · Cited by 13
Exercise in the Prevention and Treatment of Type 2 Diabetes
Kirwan, J. P., Heintz, E. C., Rebello, C. J., & Axelrod, C. L. (2023) · Comprehensive physiology · doi:10.1002/j.2040-4603.2023.tb00259.x · Cited by 18
Chilelli, N. C., Faggian, A., Favaretto, F., Milan, G., Compagnin, C., Dassie, F., Bettini, S., Roverso, M., Seraglia, R., Lapolla, A., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00156.2020 · Cited by 11
Colin, I. M., Colin, H., Dufour, I., Gielen, C.-E., Many, M., Saey, J.-P., Knoops, B., & Gérard, A.-C. (2016) · Physiological Reports · doi:10.14814/phy2.12886 · Cited by 8
“These data are consistent with observations that GLP-1RA induces lipolysis in 3T3L1 adipocytes, decreases macrophage infiltration, and improves in insulin sensitivity (Vendrell et al. 2011; Lee et al. 2012).”
ResultTargeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy
Iacobellis, G., Basilico, S., & Malavazos, A. E. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_577 · Cited by 8
Folestad, E. B., & Falkevall, A. (2024) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2024.100559 · Cited by 9
Kruglikov, I. L. (2025) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.70584 · Cited by 8
Brachs, S., Soll, D., Beer, F., Huckauf, N., Konkar, A. A., Spranger, J., Rütten, H., & Mai, K. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae151 · Cited by 7
Zishen Pill alleviates diabetes in Db/db mice via activation of PI3K/AKT pathway in the liver
Wu, Y., Sun, B., Guo, X., Wu, L., Hu, Y.-M., Qin, L., Yang, T., Li, M., Qin, T., Jiang, M., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00683-8 · Cited by 7
“Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as Liraglutide, Dulaglutide and Exenatide, act on the GLP-1R expressed on pancreatic islets to promote insulin secretion, and suppress macrophage inflammatory response [45, 46].”
BackgroundMattar, P., Jaque, C., Teske, J. A., Morselli, E., Kerr, B., Cortés, V., Baudrand, R., & Perez‐Leighton, C. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1164047 · Cited by 7
“EX4 (#1933, Tocris Bioscience) and EX3 EX3-(9-39), #2081, Tocris Bioscience) were dissolved in sterile saline and stored at -20° C in single-use aliquots.”
MethodIncretin Hormones in the Control of Immunometabolism
Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6
“WAT effects: While the administration of GLP-1R agonists affects WAT, the expression of the canonical GLP-1R on adipocytes is not widely accepted, despite some data from primary human and primate adipocytes indicating the presence of GLP-1R mRNA and protein [90,91].”
BackgroundWang, Q., Du, J., & Ma, R. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-02984-1 · Cited by 6
“GLP-1 stimulates lipolysis in 3T3-L1 adipocytes in a receptor-dependent manner, which involves downstream adenylate cyclase/cAMP signaling (Vendrell et al. 2011).”
The Link between Salivary Amylase Activity, Overweight, and Glucose Homeostasis
Erta, G., Gersone, G., Jurka, A., & Tretjakovs, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189956 · Cited by 7
“Activation of these receptors increases insulin sensitivity in adipocytes, improving glucose uptake and reducing blood glucose levels [23].”
BackgroundGLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 6
Mamontova, E. D., Michurina, S. S., Stafeev, I., Sorkina, E., Sklyanik, I. A., Koksharova, E., Menshikov, M. Y., Shestakova, M. V., & Parfyonova, Y. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s000629792103010x · Cited by 5
Patel, R., Parmar, N. B., Palit, S. P., RATHWA, N. N., & Begum, R. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02014-6 · Cited by 9
“Further, GLP-1 effects on adipocytes revealed its lipogenic and lipolytic functions [57, 58] and, interestingly, the GLP-1 receptors in the white adipose tissue are structurally and functionally different from those in the pancreas [59].”
BackgroundAdipokine-Cytokine Profile in Patients with Unstable Atherosclerotic Plaques and Abdominal Obesity
Garbuzova, E. V., Шрамко, В. С., Kashtanova, E. V., Polonskaya, Y. V., Stakhneva, E. M., Кургузов, А. В., Murashov, I. S., Chernyavsky, A. M., & Ragino, Y. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108937 · Cited by 7
“The inclusion criteria at the stage of preliminary selection of patients are as follows: male, diagnosis of coronary heart disease (CHD) verified by coronary angiography data, the presence of a history of myocardial infarction (MI) or episodes of stable angina pectoris documented by a description of…”
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
“68,69 These potential mechanisms warrant further investigation in future studies to fully elucidate the molecular pathways by which GLP-1 influences body weight and metabolic health.”
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 5
Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs
Malbert, C., Chauvin, A., Horowitz, M., & Jones, K. L. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001540 · Cited by 4
Morais, T., Seabra, A. L., Patrício, B. G., Carrageta, D. F., Guimarães, M., Nora, M. C., Oliveira, P. F., Alves, M. G., & Monteiro, M. P. (2023) · Metabolites · doi:10.3390/metabo13050587 · Cited by 5
“There is also evidence that GLP-1 has a direct effect on AT, since the GLP-1 receptor was shown to be expressed both in subcutaneous and visceral AT [6], and GLP-1 analogs were shown to induce PPAR-γ activity in a diet-dependent manner [7].”
BackgroundGLP-1 Increases Circulating Leptin Levels in Truncal Vagotomized Rats
Morais, T., Pereira, S. S., Andrade, S., Neves, D., Guimarães, M., Nora, M. C., Carreira, M. C., Casanueva, F. F., & Monteiro, M. P. (2023) · Biomedicines · doi:10.3390/biomedicines11051322 · Cited by 4
“Furthermore, GLP-1R agonists were demonstrated to potentiate the anorectic effects of leptin by acting on the CNS [50], reinforcing the synergic effects of GLP-1 and leptin [51].”
BackgroundInfluentialHaberka, M., Siniarski, A., Gajos, G., Machnik, G., Kowalówka, A. R., Deja, M. A., Okopień, B., & Gąsior, Z. T. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15797 · Cited by 9
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“Moreover, GLP-1RAs exhibit lipolytic activity when GLP-1R are present in high concentrations, such as in the visceral adipose tissue of morbidly obese patients with insulin resistance [26].”
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“…and postprandial TG levels by inhibiting insulin-mediated lipolysis [117,118,126] and promoting FA uptake in adipose tissues expressing GLP-1R [127,128], reduce VLDL-TG production and hepatic lipid accumulation [129,130], and attenuate fat mass and body weight gain in both mice and human…”
Regulation of Human Sortilin Alternative Splicing by Glucagon-like Peptide-1 (GLP1) in Adipocytes
Lui, A., Patel, R. S., Krause‐Hauch, M., Sparks, R. P., & Patel, N. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814324 · Cited by 4
“GLP1 is an incretin hormone normally found in blood at low concentrations (50 pmol/L), whose concentration is rapidly increased (peak levels of 200 pmol/L) following a meal [45].”
BackgroundPraveen Kumar Reddy, J., Tummuru, M. K. R., & Ramkumar, K. M. (2024) · Process Biochemistry · doi:10.1016/j.procbio.2024.09.001 · Cited by 3
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“Importantly, several studies have reported GLP-1R expression on both hepatocytes (liver cells) and adipocytes (fat cells) (Gupta et al., 2010; Zhang et al., 2025; Mahalingam et al., 2023; Vendrell et al., 2011; Muller et al., 2019).”
Enerji Metabolizması, Obezite ve Hormonlar
Ulutaş, D. S. S., Acar, N. E., & Yıldırım, İ. (2020) · Türkiye Spor Bilimleri Dergisi · doi:10.32706/tusbid.719671 · Cited by 4
Incretin therapy in feline diabetes mellitus – A review of the current state of research
Haller, N., & Lutz, T. A. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106869 · Cited by 4
Mi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
Derkach, K. V., Chistyakova, O. V., & Shpakov, A. O. (2014) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s002209301402001x · Cited by 2
Manning, P. J., Dixit, P., Satthenapalli, V. R., Katare, R., & Sutherland, W. H. F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00197 · Cited by 3
RetractedNaimi, S. A., & Turnock, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4836442 · Cited by 2
Mamontova, E. D., Michurina, S. S., Стафеев, Ю. С., Sorkina, E., Скляник, И. А., Koksharova, E., Menshikov, M., Shestakova, M. V., & Парфёнова, Е. В. (2021) · Biochemistry (Moscow) · doi:10.31857/s032097252103009x · Cited by 1
Soedono, S., Vo, D. H. N., Chang, J., Sharlene, S., Bayona, P. W., Kim, S., Hong, J. Y., & Cho, K. W. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.032 · Cited by 1
Liu, L., & Lu, J. L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1708109 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“Given the limited and variable expression of GLP-1R on mature adipocytes, its effects are attrib - uted to reduced energy intake via appetite suppression and delayed gastric emptying [127].”
Targeting the Epicardial Adipose Tissue
Iacobellis, G. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-40570-0_15 · Cited by 1
Sotorník, R., Brassard, P., Ménard, J., Gagnon‐Auger, M., Baillargeon, J., & Ardilouze, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16589 · Cited by 1
“30 It was also proven that GLP-1 causes vascular relaxation via both nitric oxide (NO) endothelium-dependent 31 and independent 31 pathways, and that these effects are blocked by Ex9-39.”
Effect of different surgical weight-loss interventions and ethnicity on GLP-1 secretion
Al-Rasheid, N. (2018) · UCL Discovery (University College London) · Cited by 1
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Metabolic effects of dipeptyl peptidase 4 inhibitor in type 2 diabetes
Macauley, M. (2016)
Utilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Taher, J. (2017) · TSpace (University of Toronto) · Cited by 1
Modulation of fat oxidation: nutritional and pharmacological approach
van Can, J. G. P. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20121031jc
(2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283542fb3
Efeito do sistema incretínico sobre o recrutamento de adipócitos bege
Oliveira, F. C. B. (2018) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2018.02.t.32242
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Gündüz, M. K., Kaymak, G., Kanbur, E., Berikten, D., Şahin, M. C., Şener, H., & Yerlikaya, A. (2022) · Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.21597/jist.1143528
GLP-1RA Promotes Beige Differentiation in Adipose Tissue
刘, 臻. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143795
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
J, P., Tummuru, M., & Ramkumar, K. (2025) · Biotechnology progress (Print) · doi:10.1002/btpr.3529
“5,6 This mechanism improves glycemic control and lowers blood sugar levels in T2DM patients.”
Król, M., Żychowska, J., Łagowski, R., Kupnicka, P., Simińska, D., & Chlubek, D. (2023) · Pomeranian Journal of Life Sciences · doi:10.21164/pomjlifesci.965 · Cited by 2
IMPACT OF CELEBRITY STATEMENTS ON INTERNET SEARCHES ON THE USE OF SEMAGLUTIDE FOR WEIGHT LOSS
Local Health Unit of Trapani, A. T., Provenzano, S., Santangelo, O. E., & Regional Health Care and Social Agency of Lodi, A. L. (2025) · Avicenna Bulletin · doi:10.25005/2074-0581-2025-27-2-373-384
Hernández-Flandes, R. N., Tapia-González, M. D. L. Á., Hernández-Lara, L., Madrigal‐Santillán, E., Morales‐González, Á., Anguiano‐Robledo, L., & Morales‐González, J. A. (2025) · Diabetology · doi:10.3390/diabetology6070067 · Cited by 1
Bzoma, M., Bochenek, H., Kamiński, P., Czerepak, I., Gugulska, J., Bielicka, A., Szwarc, T., Kałwik, M., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3493
Antsiferova, D. M., Ametov, A. S., Koteshkova, O. M. K., Ромашкина, Л. П., & Antsiferov, M. B. (2026) · Diabetes Mellitus · doi:10.14341/dm13441
Yang, S.-I., Kim, S. W., Son, K., Lee, S., Kim, J.-G., Roh, J.-I., & Sung, Y. C. (2026) · Nature Communications · doi:10.1038/s41467-026-71080-0 · Cited by 1
Dobrzycka, M., & Karczewska‐Kupczewska, M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02185-1 · Cited by 3
“Acting via their respective receptors (GLP-1R and GIP-R), they contribute to up to 70% of postprandial insulin secretion in a glucose-dependent manner (the incretin effect) in healthy individuals [103].”
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Rosen, C. B., & Gee, D. W. (2026) · Advances in Surgery · doi:10.1016/j.yasu.2026.03.011
Peptide-functionalized nanoemulsions with exendin-4 as a model ligand
Holler, N., Gesslbauer, B., Tam‐Amersdorfer, C., Letofsky‐Papst, I., Mayrhofer, C., Andreae, F., & Zimmer, A. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100598
“Of note, these effects are attenuated by adenylate cyclase (AC) inhibition, implicating a cAMP-dependent mechanism (El Bekay et al., 2016; Vendrell et al., 2011).”
Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
Lobato, C. B., & Holst, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00004-4
Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Cruz, A. J. L., & Yuan, L. (2026) · Cells · doi:10.3390/cells15151377 · Cited by 1
“…receptor transcript in human adipose tissue and reported effects of GLP-1 receptor agonists on adipocyte lipolysis, adipogenesis, and inflammation in ex vivo systems [122], whereas other studies using highly specific antibodies and functional assays have found no evidence of direct signaling [123].”
Abud, G. F., de Freitas, E. C., & Stanford, K. I. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00756-x
“…may originate, at least in part, from non-adipocyte cell populations within the tissue, consistent with reports that GLP-1R expression in human vWAT is enriched within the SVF, which includes mesenchymal stem cells, preadipocytes, fibroblasts, vas - cular endothelial cells, and immune cells [69].”
Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss
Gupta, A. K., Kaur, J., Piguet, V., & Mirmirani, P. (2026) · Biology · doi:10.3390/biology15181642
Metadata
- Authors
- Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., Simó, R., Selva, D. M., Malagón, M. M., & Tinahones, F. J.
- Affiliations
- Instituto de Salud Carlos III (ES)
- University Hospital of Tarragona Joan XXIII (J.V., A.M., X.E., G.P.), IISPV, Rovira i Virgili University, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, 43007 Tarragona, Spain
- Consejo Superior de Investigaciones Científicas (ES)
- Laboratorio de Investigación Biomédica (R.E.B., E.G.-F., M.G., Y.J.-G., F.J.T.), Hospital Virgen de la Victoria, 29010 Málaga, Spain
- Department of Cell Biology, Physiology, and Immunology (Y.J.-G., M.M.M.), Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CB06/03/0020) and Instituto de Salud Carlos III, Instituto de Investigación Biomédica, University of Córdoba, 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-08-23
- Volume
- 152
- Issue
- 11
- Pages
- 4072-4079
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2143149722
- Cited by
- 173
- References
- 28
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 11 · 2021: 11 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 12 · 2013: 11 · 2012: 5
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
- Funders
- Ministerio de Ciencia e Innovación (SAF-2009-10461)
- Servicio Andaluz de Salud
- Instituto de Salud Carlos III (PS09/00997, PI070953)
- European Regional Development Fund
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- GLP-1 receptor, adipose tissue, obesity, insulin resistance, lipolysis, lipogenesis, 3T3-L1 adipocytes, biliopancreatic diversion, insulin sensitivity, visceral adipose tissue, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adipose Tissue, Animals, Cells, Cultured, Humans, Insulin Resistance, Obesity, Morbid, Prospective Studies, Adipocytes, Receptors, Glucagon, 3T3-L1 Cells, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.